FDA Approves rfxcel for Verification Router Service (VRS) Pilot
rfxcel, the global leader in supply chain compliance and serialization solutions, has been approved by the U.S. Food and Drug Administration (FDA) to conduct a pilot to extend the testing of the Verification Router Service (VRS) for saleable returns.
The VRS specifications outline interoperability standards that enable a network of VRS providers to meet the 2019 saleable returns requirements of the Drug Quality and Security Act (DSCSA). Working together, the Healthcare Distribution Alliance (HDA) and pharmaceutical stakeholders defined the VRS standards and tested the VRS network to confirm readiness for the upcoming requirements.
rfxcel will work with pharmaceutical supply chain partners of all sizes to extend the testing to ensure that all edge-cases are verified and ensure that interoperability readiness is quantified.
As part the pilot, rfxcel will share the details of its VRS test cases with all VRS providers to ensure they have a common detailed set of test cases. rfxcel will work with the providers to verify the test conditions to enable maximum readiness of the VRS network across all VRS providers.
“We are excited to continue the effort started by the HDA, and we are honored to be approved by the FDA for the VRS pilot,” said rfxcel CEO Glenn Abood. “The pilot seeks to measure and ensure the seamless interoperability between VRS providers across a broad range of use cases. Complete and consistent verification of the use cases is critical to successfully meeting the DSCSA saleable returns requirement.
“We are working with other VRS providers and supply chain partners of all sizes to ensure proper representation in the VRS pilot,” Abood continued. “As a first step, rfxcel will begin sharing our test cases with all VRS providers to set the stage for an open work environment among all participants.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance